Company: ECIA
Filing Date: 2025-07-14
Form Type: DEF 14A
Source: 0001079973-25-001145
Chunk: 7

Company: ENCISION INC
Filing Date: 2025-07-14
Form: DEF 14A
Chunk 7
---
 as our President & Chief Executive Officer and a director since December 2013. Mr. Trudel has over 35 years of experience in
the surgical devices marketplace. Since 2008, and until becoming President & Chief Executive Officer of Encision Inc., Mr. Trudel
had been employed by Covidien, a large global healthcare products company serving in various roles including Global Marketing for surgical
energy and stapling products. Prior to joining Covidien, Mr. Trudel held leadership roles with CONMED Electrosurgery, SilverGlide
Surgical Technologies, and Stryker. He holds a B.S. from the University of Connecticut and an M.B.A from the University of Bridgeport,
CT. We believe that Mr. Trudel’s extensive business acumen, executive experience with public companies, and his widespread experience
in medical devices make him uniquely qualified to serve as a director.

Director Meetings

During the fiscal year ended
March 31, 2025, our board of directors met in person one time and had three telephonic meetings. There were four meetings of the audit
committee, one meeting of the compensation committee and one meeting of the nominating committee. The audit committee held four telephonic
meetings with our independent auditors. Each director attended at least 75% of the aggregate of the total number of meetings of the board
and the board committees on which he served during fiscal year 2025.

We encourage our incumbent
directors to attend the Annual Meeting of Shareholders, subject to their travel schedule and other demands on their time. All our directors
attended the 2024 Annual Meeting of Shareholders.

Our board of directors determines
whether a director is independent through a broad consideration of facts and circumstances, including an assessment of the materiality
of any relation between us and a director not merely from the director’s standpoint, but also from that of persons or organizations
with which the director has an affiliation. In making this determination, the board of directors adheres to the independence criteria
under applicable New York Stock Exchange, Inc. (“NYSE”) rules. Using these rules, our board of directors has determined that
Robert H. Fries, Vern D. Kornelsen and Patrick W. Pace, M.D. qualify as independent directors.

Compensation of Directors

Our independent directors
receive $1,250 a quarter for their services and are reimbursed for their out-of-pocket expenses incurred in connection with their service
as directors. Option or equity grants